Wednesday, December 30, 2009

Eli Lilly's Wrong Road With Livalo

›
Eli Lilly (LLY-$35.01) chairman and chief executive office John Lechleiter stated that the drug maker’s deal to co-promote Japan-based Kowa...
Wednesday, December 23, 2009

Ford Motor to Ask Santa For More Common Stock

›
The VEBA-UAW deal eerily resembles other debt reduction initiatives undertaken by Ford Motor Company (F-$10.00) — improving liquidity and r...
1 comment:
Friday, December 18, 2009

Tamiflu Infected With the Truth -- How Debilitating to Health of Roche and Gilead Sciences?

›
Gilead Sciences ($43.20) receives a blended royalty on sales of Tamiflu (oseltamivir), marketed by Roche Holdings . Leveraging global conc...
Wednesday, December 16, 2009

How Much For Life? Allos Therapeutics Says $30,000 - Per Month

›
The cost of Folotyn (pralatrexate injection) runs about $120,000 a year, a price tag that few drugs for incurable, rare cancers can match. ...
Monday, December 14, 2009

Abbott Labs Looks to TriLipix and Certriad for Future Success'

›
The success behind Abbott Laboratories’ (ABT-$53.78) patent-expiry settlement with Teva Pharmaceutical is that it buys the drug maker more...
Tuesday, December 08, 2009

GameStop's Gamer Hell

›
In fiscal 2008, GameStop (GME-$21.35) generated approximately 40 percent of its sales and 56 percent of its operating profit during the all...
1 comment:
Monday, December 07, 2009

Valero 'Fills 'Er Up With Ethanol Profits

›
Valero (VLO-$16.36) is looking to improve margins by shifting its crude diet away from heavy sours to lighter “sweet” (lower sulfur content...
Sunday, December 06, 2009

More on Novartis' Promising MS Drug Fingolimod

›
Novartis’ (NVS-$55.78) fingolimod, first in a new class of immunomodulatory drugs called S1P-receptor modulators, reduces circulating level...
Wednesday, December 02, 2009

Second Life for Pfizer's HIV Drug Selzentry

›
Pfizer’s (PFE-$18.85) anti-HIV drug Selzentry is now approved for combination use with other antiretroviral agents for treatment-naïve pat...
Tuesday, December 01, 2009

Jacked up Dreams at Incyte

›
In the newly inked commercial deal with Novartis, drug designer Incyte (INCY-$8.39) retained exclusive rights for the development and poten...
Monday, November 30, 2009

Patterson-UTI Expands Rigging Activity in Shale Basins

›
The drilling slowdown has eroded Patterson-UTI Energy’s (PTEN-$15.25) U.S. land rig market share, which is down some 50 percent in the last...
Thursday, November 26, 2009

Novartis Breathes Life Into Blood Pressure Franchise

›
Novartis AG (NVS-$55.85) loses patent protection for its $4.4 billion blood pressure medicine Diovan (valsartan) in the major countries of...
Monday, November 23, 2009

Johnson & Johnson Itches for Successful Stelara Launch

›
Stelara (ustekinumab), the Johnson & Johnson (JNJ-$62.76) drug approved for the treatment of moderate-to-severe plaque psoriasis in ad...
Friday, November 20, 2009

Should Genzyme Hire Beer Girls Instead?

›
Genzyme (GENZ-$49.63) has already spent more than $1 billion in the last two years to build new and bigger bioreactors — notably in the U.S...
Thursday, November 19, 2009

ITT Educational Services' Healthy Assets Hide Growing Loan Defaults

›
Do not be mislead by ITT Educational Services (ESI-$93.00) impressive balance sheet or 27 percent gains in new student enrollments for the ...
Friday, November 13, 2009

Biogen Idec's Social Media Successes

›
In the battle for market share and sales, Biogen Idec (BIIB-$46.75) has successfully conveyed the Tysabri message to providers and potenti...
Thursday, November 12, 2009

Generics Pressure Johnson & Johnson -- Motrin Anyone?

›
Johnson & Johnson ’s Invega (paliperidone) is no Dorothy Hamill poised to skate away with the gold anytime soon. The heralded successo...
Wednesday, November 11, 2009

MannKind Inhales -- Exhales, Awaits FDA Meeting

›
MannKind (MNKD-$6.58) is seeking FDA approval of Afresa for the treatment of adults with type 1 or type 2-diabetes. Afresa is a drug-devic...
Sunday, November 08, 2009

Teva Pharmaceutical Learns Legal Sword Cuts Both Ways

›
Teva Pharmaceutical (TEVA-$52.03) became the world’s largest generic manufacturer through an unflinching willingness to knock down the pate...
Wednesday, November 04, 2009

Can BioCryst Pharma's Peramivir Boost Obama's Poll Numbers?

›
Does the totality of scientific evidence on Biocryst Pharma’ s (BCRX-$10.00) peramivir support the intravenous administration of the drug ...